Genome Publications
https://doi.org/10.61096/ 978-81-981372-2-7_6

Chapter 6

Endocrine and Metabolic Pharmacology

Dr. SriKalyani Vemuri
Associate Professor, Department of Pharmaceutical Analysis,
Sri Venkateswara College of Pharmacy, Madhapur, Hyderabad.

Varaha Narasimharao. C
Associate professor, Shantiniketan college of Pharmacy,
Dhotre, Ahilyanahar, Maharashtra, India

Abstract: This chapter provides a comprehensive overview of endocrine and metabolic pharmacology, focusing on the pharmacological management of major hormonal and metabolic disorders such as diabetes mellitus, obesity, thyroid dysfunction, adrenal insufficiency, and pituitary disorders. It emphasizes the interplay of hormonal regulation, pathophysiological mechanisms, and the evolution of therapeutic agents targeting key pathways. Modern pharmacological strategies include insulin analogs, oral antidiabetic agents, incretin-based therapies, GLP-1 receptor agonists, and SGLT2 inhibitors, many of which offer cardiometabolic benefits beyond glycemic control. Obesity pharmacotherapy is explored through central and peripheral-acting agents, with particular focus on the efficacy of GLP-1/GIP dual agonists like tirzepatide. The chapter also delves into thyroid and adrenal therapies, hormone biosimilars, pituitary-targeted agents, and the emergence of FGF21 analogs and hormonal gene therapies. Emphasis is placed on pharmacogenomics, drug interactions, monitoring protocols, and individualized treatment approaches driven by genetic, metabolic, and behavioural factors. Through integration of omics technologies, digital tools, and AI-driven platforms, the future of endocrine pharmacology is increasingly geared toward precision, safety, and long-term disease modification.

Keywords: Diabetes Mellitus, GLP-1 Receptor Agonists, Obesity Pharmacotherapy, Hormonal Gene Therapy, Precision Endocrine Medicine, Pharmacogenomics

Citation: SriKalyani Vemuri, Varaha Narasimharao. C. Endocrine and Metabolic Pharmacology. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems.* Genome Publications. 2025; Pp45-62. https://doi.org/10.61096/978-81-981372-2-7_6

6.0 INTRODUCTION

Endocrine and metabolic pharmacology plays a crucial role in the management of diseases characterized by hormonal imbalances and metabolic dysfunctions, including diabetes mellitus,

obesity, thyroid disorders, and adrenal insufficiency. These conditions contribute significantly to global morbidity and mortality and are often interconnected through shared mechanisms such as chronic inflammation, oxidative stress, and insulin resistance [1]. A core concern in metabolic disorders is the rising incidence of metabolic syndrome, defined by a constellation of central obesity, dyslipidemia, hypertension, and impaired glucose tolerance [2]. This syndrome is a known precursor for both type 2 diabetes mellitus (T2DM) and cardiovascular diseases, making early pharmacologic intervention essential.

The hormonal regulation of metabolism is a complex network involving polyhormonal feedback loops that include insulin, glucagon, leptin, ghrelin, adiponectin, and incretins. Disruption in these axes due to genetic, environmental, or autoimmune causes results in disorders such as diabetes, thyroid dysfunction, adrenal insufficiency, and growth hormone abnormalities [3]. These disruptions underscore the need for precise and individualized pharmacologic strategies.

Recent advances in drug development have introduced several novel agents that target specific molecular pathways. The advent of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists has revolutionized the treatment of T2DM by not only lowering blood glucose but also improving cardiovascular and renal outcomes [4]. Likewise, long-acting insulin analogs, combination hormone therapies, and biosimilar formulations have improved glycemic control and patient compliance [5].

Precision medicine and pharmacogenomics are increasingly being incorporated into clinical endocrinology. Genetic polymorphisms influencing drug metabolism (e.g., CYP450 variants) and hormone receptor sensitivity are being used to predict therapeutic response and adverse effects, particularly in diabetes and thyroid therapy [6]. Furthermore, integration of digital health technologies such as continuous glucose monitoring (CGM), smart insulin pens, and mobile applications enhances therapeutic precision and patient engagement [7].

The therapeutic landscape is expanding to include metabolic peptides such as fibroblast growth factor 21 (FGF21) analogs and novel gene therapy vectors that may offer curative approaches for intractable endocrine disorders [8]. These innovations, coupled with the growing application of artificial intelligence in drug development and personalized care, position endocrine pharmacology at the forefront of modern medicine.

This chapter provides a comprehensive and evidence-based review of major therapeutic classes used in endocrine and metabolic disorders. Each section addresses pharmacodynamics, pharmacokinetics, clinical applications, drug interactions, and emerging therapies, with a focus on patient-centered, precision-based approaches.

6.1 Diabetes Mellitus and Insulin Therapy

Diabetes mellitus encompasses a group of metabolic disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Type 1 diabetes mellitus (T1DM) arises from autoimmune destruction of pancreatic β-cells, leading to absolute insulin deficiency. In contrast, type 2 diabetes mellitus (T2DM) involves progressive insulin resistance and relative insulin deficiency, frequently associated with obesity and metabolic syndrome [9].

Insulin therapy remains the cornerstone of T1DM treatment and is frequently employed in advanced T2DM. Modern insulin preparations are classified based on their pharmacokinetic profiles: rapid-acting (lispro, aspart, glulisine), short-acting (regular insulin), intermediate-acting (NPH), and long-acting analogs (glargine, detemir, degludec) [10]. Basal-bolus regimens, which combine a long-

acting basal insulin with rapid-acting prandial insulins, provide the most physiological glycemic control and are considered the gold standard in T1DM [11].

Insulin analogs offer superior pharmacodynamic profiles compared to conventional human insulin. They exhibit more predictable absorption, reduced glycemic variability, and lower risk of nocturnal hypoglycemia, especially with long-acting formulations like degludec, which offers a duration of action exceeding 42 hours [12]. The use of insulin pumps and continuous subcutaneous insulin infusion (CSII) systems has further improved flexibility and glycemic control in selected patients [13].

One of the most significant risks of insulin therapy is hypoglycemia. Mild episodes are managed with oral carbohydrates, while severe hypoglycemia may require intramuscular glucagon or intravenous dextrose. Patient education and regular glucose monitoring are critical components of safe insulin use [14]. The integration of CGM with insulin pump technology in closed-loop systems ("artificial pancreas") has shown promise in minimizing hypoglycemia while maintaining tight glucose control [15].

Ongoing research is focused on developing glucose-responsive insulins that release the hormone in response to ambient blood glucose levels, thereby mimicking endogenous pancreatic function more closely and reducing the risk of hypoglycemia [16]. Another frontier involves hepatic-targeted insulin analogs, designed to replicate the physiological portal-peripheral insulin gradient [17].

Despite technological advancements, successful insulin therapy requires individualized titration based on meal patterns, physical activity, stress, illness, and concurrent medications. Clinicians must consider patient-specific factors such as renal function, comorbidities, and cognitive ability when designing insulin regimens [18]. Biosimilar insulins are increasingly used to reduce cost burden without compromising efficacy or safety, thereby expanding access in resource-limited settings [19].

With the convergence of biotechnology and digital health, the future of insulin therapy is likely to be shaped by AI-assisted dosing algorithms, CGM-integrated dosing platforms, and next-generation smart insulin delivery devices [20].

6.2 Oral Antidiabetic Agents and Incretin Mimetics

Oral antidiabetic agents (OADs) form the backbone of pharmacologic therapy in type 2 diabetes mellitus (T2DM), particularly during the early and middle stages of the disease when endogenous insulin secretion is partially preserved. Over the past two decades, the armamentarium of OADs has significantly expanded to include agents that not only improve glycemic control but also confer cardiovascular and renal protection. These include sodium-glucose cotransporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), among others [21].

SGLT2 inhibitors such as dapagliflozin, empagliflozin, and canagliflozin act on the proximal renal tubules to inhibit glucose reabsorption, resulting in glucosuria and reduced plasma glucose levels. These agents are insulin-independent, allowing them to be used across a wide range of insulin resistance and β-cell functionality [22]. Moreover, clinical trials have demonstrated substantial reductions in hospitalization for heart failure, progression of diabetic kidney disease, and all-cause mortality with SGLT2 inhibitors, making them preferred agents in patients with T2DM and cardiorenal comorbidities [23].

DPP-4 inhibitors, including sitagliptin, vildagliptin, saxagliptin, and linagliptin, exert their effects by prolonging the half-life of endogenous incretin hormones, particularly GLP-1 and glucose-

dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion and inhibit glucagon release in a glucose-dependent manner, thereby reducing the risk of hypoglycemia [24]. DPP-4 inhibitors are generally weight-neutral and well-tolerated, making them suitable for elderly patients and those with renal impairment, with dose adjustments required in most agents except linagliptin [25].

GLP-1 receptor agonists such as exenatide, liraglutide, dulaglutide, and semaglutide mimic the actions of endogenous GLP-1. They enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. These mechanisms result in both glycemic control and weight reduction. Importantly, large outcome trials have demonstrated that certain GLP-1 RAs, notably liraglutide and semaglutide, reduce major adverse cardiovascular events (MACE) in high-risk populations [26].

GLP-1 RAs are administered subcutaneously and are now available in both daily and weekly formulations. The advent of oral semaglutide has expanded accessibility, although gastrointestinal side effects such as nausea and vomiting remain common. Tolerability can often be improved through gradual dose titration [27]. The dual benefits of GLP-1 RAs on glucose and weight make them particularly attractive in obese individuals with T2DM, and their use is expanding into non-diabetic obesity treatment paradigms [28].

Combination therapies, such as fixed-dose combinations of metformin with SGLT2 inhibitors or DPP-4 inhibitors, simplify treatment regimens and improve adherence. Triple therapy combining metformin, a GLP-1 RA, and an SGLT2 inhibitor is emerging as a comprehensive approach to address the multifactorial nature of T2DM, targeting glycemia, weight, blood pressure, and cardiovascular risk simultaneously [29].

Incretin-based therapies are also being explored for combination with basal insulin, offering the potential to reduce insulin doses and minimize weight gain and hypoglycemia. Fixed-ratio combinations, such as insulin degludec/liraglutide and insulin glargine/lixisenatide, offer simplified once-daily dosing with synergistic effects [30].

Ongoing research is focused on dual and triple incretin receptor agonists targeting GLP-1, GIP, and glucagon receptors. Tirzepatide, a dual GLP-1/GIP receptor agonist, has demonstrated superior glycemic and weight outcomes compared to GLP-1 monotherapy and is being hailed as a major breakthrough in diabetes pharmacotherapy [31]. These multi-receptor agents aim to exploit the synergistic metabolic actions of incretin hormones for enhanced efficacy.

In summary, the landscape of oral and injectable antidiabetic therapy has evolved from mere glycemic control to a more holistic approach addressing cardiometabolic risk. The integration of pharmacodynamic insights with clinical trial data allows for individualized therapy that aligns with patient-specific goals and comorbidities.

6.3 Obesity Pharmacotherapy

Obesity is a chronic, relapsing, and multifactorial disease characterized by excessive adipose tissue accumulation, leading to increased morbidity and mortality. It is a major risk factor for type 2 diabetes mellitus (T2DM), cardiovascular disease, hypertension, dyslipidemia, non-alcoholic fatty liver disease, obstructive sleep apnoea, and several cancers. The management of obesity requires a multidisciplinary approach that includes lifestyle interventions, behavioural therapy, and pharmacological agents when non-pharmacologic methods are inadequate [32].

Pharmacologic options are recommended for individuals with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with associated comorbidities. The mechanism of anti-obesity drugs typically

involves appetite suppression, increased satiety, decreased absorption of nutrients, or stimulation of energy expenditure. Central to current pharmacotherapy is the manipulation of neuroendocrine pathways involving leptin, ghrelin, neuropeptide Y, melanocortins, and GLP-1 [33].

GLP-1 receptor agonists such as liraglutide (3.0 mg) and semaglutide (2.4 mg weekly) have emerged as leading pharmacologic treatments for obesity. These agents promote satiety by acting on hypothalamic centers and delay gastric emptying, resulting in decreased caloric intake. In large clinical trials such as SCALE and STEP, liraglutide and semaglutide showed mean weight reductions of up to 15% from baseline [34]. Semaglutide, in particular, has demonstrated superior efficacy and is now considered a first-line pharmacologic option for chronic weight management in individuals with or without diabetes [35].

Appetite suppressants, also known as anorectics, include sympathomimetic agents such as phentermine and phentermine-topiramate extended-release. These act primarily via norepinephrine release, stimulating the hypothalamus to reduce hunger. While effective, their use is limited by potential cardiovascular side effects and the risk of dependence, necessitating careful patient selection and monitoring [36].

Other agents include bupropion/naltrexone, a combination that modulates the reward system and pro-opiomelanocortin neurons, leading to reduced food intake and increased energy expenditure. Orlistat, a gastrointestinal lipase inhibitor, reduces dietary fat absorption by approximately 30% and is the only anti-obesity agent with peripheral action. However, it is associated with gastrointestinal side effects and fat-soluble vitamin malabsorption [37].

The development of dual and triple agonists is revolutionizing obesity pharmacotherapy. Tirzepatide, a dual GLP-1/GIP receptor agonist, has demonstrated weight loss exceeding 20% in some clinical trials, surpassing all existing pharmacotherapies. The agent combines glycemic efficacy with robust effects on satiety and body weight, suggesting utility in both diabetic and non-diabetic populations [38].

Combination therapies are gaining momentum as they exploit complementary mechanisms to enhance efficacy. Trials exploring GLP-1 agonists with SGLT2 inhibitors or other neurohormonal modulators have shown additive or synergistic effects on weight reduction. Furthermore, fixed-dose combinations improve adherence by reducing pill burden and simplifying regimens [39].

Clinical use of anti-obesity drugs requires ongoing monitoring for efficacy and tolerability. Weight loss of ≥5% within three months of initiating therapy is typically used as a benchmark for treatment continuation. Pharmacologic treatment should always be accompanied by behavioral counseling, dietary modifications, and physical activity to achieve and sustain therapeutic outcomes [40].

With obesity now recognized as a disease entity, not merely a lifestyle issue, the pharmacologic pipeline is expanding rapidly. Investigational agents include amylin analogs (e.g., cagrilintide), MC4R agonists, and centrally acting melanocortin receptor modulators, aimed at addressing genetic and hypothalamic obesity [41]. Gene therapy and microbiota modulation also represent future strategies for weight regulation.

The integration of pharmacotherapy into long-term obesity management holds promise for reducing the burden of obesity-related complications and improving quality of life. Personalized treatment selection, guided by genetic, metabolic, and behavioral profiling, represents the future of obesity pharmacology.

6.4 Thyroid and Antithyroid Drugs

Thyroid disorders are among the most prevalent endocrine conditions worldwide, primarily manifesting as hypothyroidism and hyperthyroidism. These disorders are the result of either deficient or excessive thyroid hormone synthesis and secretion, affecting basal metabolic rate, cardiovascular function, growth, and neurocognitive processes. Pharmacologic interventions aim to restore and maintain euthyroid status, prevent complications, and improve quality of life [42].

Hypothyroidism, most commonly caused by autoimmune thyroiditis (Hashimoto's thyroiditis), is characterized by elevated thyroid-stimulating hormone (TSH) and low circulating thyroxine (T4) levels. The standard treatment is levothyroxine (LT4), a synthetic form of T4, administered orally once daily. LT4 is converted peripherally to the active hormone triiodothyronine (T3), mimicking physiologic hormone production [43]. The pharmacokinetics of LT4 are influenced by gastrointestinal absorption, which can be altered by food, medications (e.g., calcium, iron), and gastric pH [44]. Therefore, it is recommended to take levothyroxine on an empty stomach, preferably 30–60 minutes before breakfast.

Dose titration is guided by serum TSH measurements, typically evaluated 6–8 weeks after therapy initiation or dose adjustment. In elderly patients or those with ischemic heart disease, therapy is initiated at low doses and gradually increased to avoid exacerbation of cardiac symptoms. Special formulations like soft gel capsules or liquid LT4 are available for patients with malabsorption or intolerance to tablet forms [45].

Hyperthyroidism, often resulting from Graves' disease or toxic multinodular goiter, is treated with antithyroid drugs (ATDs) such as methimazole (MMI) and propylthiouracil (PTU). These thionamides inhibit thyroid peroxidase, blocking iodination of tyrosine residues and coupling of iodotyrosines in thyroglobulin, essential steps in thyroid hormone synthesis [46]. MMI is preferred due to its longer half-life, allowing once-daily dosing and fewer side effects. PTU is reserved for use during the first trimester of pregnancy due to lower teratogenic risk and for managing thyroid storm due to additional inhibition of peripheral T4-to-T3 conversion [47].

Monitoring during ATD therapy includes assessment of free T4 and TSH every 4–6 weeks. ATDs carry the risk of rare but serious adverse effects such as agranulocytosis and hepatotoxicity. Patients are advised to report symptoms such as fever, sore throat, or jaundice immediately. Mild side effects like rash or arthralgia may resolve with antihistamines or dose adjustments [48].

For patients intolerant to or failing medical therapy, radioactive iodine (RAI) ablation is an effective alternative, especially in Graves' disease and toxic nodular goiter. RAI selectively destroys hyperfunctioning thyroid tissue. However, it may exacerbate Graves' ophthalmopathy and is contraindicated in pregnancy and lactation [49]. Long-term hypothyroidism post-ablation is common, necessitating LT4 replacement.

Iodine-containing preparations, such as potassium iodide (Lugol's solution), are used preoperatively in thyroidectomy to reduce vascularity or in thyroid storm as adjunct therapy. These agents acutely inhibit thyroid hormone release but are unsuitable for long-term use due to escape phenomenon and potential for paradoxical thyrotoxicosis (Jod-Basedow effect) [50].

Emerging strategies include TSH receptor antagonists, monoclonal antibodies targeting autoimmune mechanisms in Graves' disease, and novel small molecules that selectively modulate thyroid hormone receptors. Research is ongoing into thyromimetics T3 analogs selective for β-receptors which may have utility in metabolic disorders without adverse cardiac effects [51].

In both hypothyroid and hyperthyroid patients, drug selection and dosing must be individualized based on age, etiology, comorbidities, pregnancy status, and response to therapy.

Lifelong follow-up is often necessary to monitor for relapse, remission, or progression to permanent thyroid dysfunction.

6.5 Adrenal Hormones and Corticosteroid Therapy

The adrenal glands secrete glucocorticoids, mineralocorticoids, and androgens, which are essential for metabolic regulation, fluid balance, stress response, and immune modulation. Pharmacologic replacement or suppression of these hormones is crucial in treating adrenal insufficiency, inflammatory and autoimmune diseases, and certain malignancies. Corticosteroids, the synthetic analogs of endogenous adrenal hormones, are classified into glucocorticoids (e.g., hydrocortisone, prednisolone, dexamethasone) and mineralocorticoids (e.g., fludrocortisone) based on their receptor affinities and physiological effects [52].

Glucocorticoids exert their actions through intracellular glucocorticoid receptors, modulating gene transcription involved in glucose metabolism, immune response, inflammation, and tissue repair. Their anti-inflammatory and immunosuppressive properties make them indispensable in managing asthma, rheumatoid arthritis, inflammatory bowel disease, nephrotic syndrome, and organ transplantation [53]. However, long-term use is associated with significant adverse effects, including osteoporosis, hyperglycemia, hypertension, muscle wasting, Cushingoid features, and increased susceptibility to infections [54].

The choice of glucocorticoid depends on the desired potency, half-life, and indication. Hydrocortisone, with its short half-life and mineralocorticoid activity, is preferred for adrenal insufficiency, mimicking diurnal cortisol variation. Prednisolone is commonly used for systemic inflammation, while dexamethasone, a long-acting agent, is used in cerebral edema, chemotherapy-induced nausea, and diagnostic suppression tests like the dexamethasone suppression test for Cushing's syndrome [55].

Mineralocorticoid replacement, primarily using fludrocortisone, is required in primary adrenal insufficiency (Addison's disease) to regulate sodium and potassium homeostasis and maintain intravascular volume. Fludrocortisone acts on the distal renal tubules to promote sodium reabsorption and potassium excretion. Electrolyte monitoring is crucial to avoid hypokalemia and hypertension [56].

Patients with chronic adrenal insufficiency require life-long glucocorticoid replacement, with dose adjustments during stress, illness, or surgery to prevent adrenal crisis. Education on "sick day rules," emergency hydrocortisone injection, and use of medical alert identification is vital for safety [57].

Abrupt withdrawal of long-term corticosteroids can precipitate hypothalamic-pituitary-adrenal (HPA) axis suppression and adrenal crisis. Therefore, tapering regimens are necessary to allow recovery of endogenous cortisol production. The tapering schedule varies depending on the dose, duration, and underlying disease state [58].

Monitoring parameters during corticosteroid therapy include blood pressure, blood glucose, bone mineral density, ocular pressure, and infection risk. Bone loss is a particularly concerning adverse effect; prophylactic calcium, vitamin D, and bisphosphonates are recommended for patients on chronic therapy [59].

Newer formulations, such as modified-release hydrocortisone, aim to mimic circadian cortisol secretion and improve metabolic outcomes in adrenal insufficiency. Additionally, selective glucocorticoid receptor modulators (SEGRMs) are under investigation for anti-inflammatory effects with reduced side-effect profiles [60].

Glucocorticoids are also used diagnostically. For example, the cosyntropin stimulation test assesses adrenal responsiveness, while the overnight dexamethasone suppression test is used to evaluate hypercortisolism. These applications highlight the hormone's broad clinical utility beyond replacement [61].

In oncology, corticosteroids are used for lymphoid malignancies, symptomatic relief in brain metastases, and as antiemetics in chemotherapy regimens. However, they may promote tumor progression in some cancers and blunt immune responses, necessitating careful risk-benefit assessment [62].

In summary, adrenal hormone pharmacology involves a delicate balance between efficacy and adverse effects. Individualized therapy, dose titration, and vigilant monitoring are essential for optimizing therapeutic outcomes and minimizing complications.

6.6 Pituitary Hormone Agents

The pituitary gland, often termed the "master gland," regulates several vital endocrine functions through anterior and posterior pituitary hormones. Disorders involving the pituitary may result in hormone excess or deficiency, requiring precise pharmacologic modulation. Agents targeting growth hormone (GH), prolactin, and the adrenocorticotropic hormone (ACTH) axis are the most clinically significant among pituitary-directed drugs [63].

Growth hormone (GH) analogs, such as somatropin, are used for GH deficiency in children and adults. GH exerts anabolic effects by stimulating hepatic production of insulin-like growth factor 1 (IGF-1), promoting linear growth, lipolysis, protein synthesis, and bone mineralization. Somatropin is administered subcutaneously, with dosing based on weight, age, and IGF-1 levels. Indications include Turner syndrome, Prader-Willi syndrome, chronic kidney disease-related growth failure, and adult GH deficiency [64].

In contrast, GH excess, as seen in acromegaly, is managed using somatostatin analogs (e.g., octreotide, lanreotide), GH receptor antagonists (e.g., pegvisomant), and occasionally dopamine agonists (e.g., cabergoline). Somatostatin analogs inhibit GH release from the pituitary, while pegvisomant blocks GH receptor signaling, reducing circulating IGF-1 levels. These agents have improved disease control and reduced need for surgery or radiotherapy [65].

Prolactinomas, the most common pituitary adenomas, result in hyperprolactinemia and reproductive dysfunction. Dopamine agonists like bromocriptine and cabergoline suppress prolactin secretion by stimulating D2 receptors on lactotroph cells. Cabergoline is favored for its longer half-life and better tolerability. These agents are effective in restoring gonadal function, normalizing prolactin levels, and reducing tumor size in most patients [66].

ACTH-related disorders require either stimulation or suppression, depending on the pathology. Cosyntropin, a synthetic ACTH analog, is used diagnostically to evaluate adrenal reserve in suspected adrenal insufficiency. A subnormal cortisol response indicates primary adrenal failure or secondary hypoadrenalism due to pituitary dysfunction [67].

In Cushing’s disease, characterized by pituitary ACTH overproduction, medical therapies include pasireotide, a somatostatin analog targeting somatostatin receptor subtype-5, and cabergoline, which inhibits ACTH secretion. Metyrapone, ketoconazole, and osilodrostat inhibit adrenal cortisol synthesis and serve as adjuncts when surgery is contraindicated or incomplete [68].

Desmopressin (DDAVP), a synthetic analog of vasopressin, is used in central diabetes insipidus to replace deficient antidiuretic hormone (ADH). It is also employed in hemophilia A and von

Willebrand disease type 1 due to its ability to increase factor VIII and von Willebrand factor release. Desmopressin is available in intranasal, oral, and parenteral formulations [69].

For growth hormone-releasing hormone (GHRH) deficiency or resistance, tesamorelin, a GHRH analogue, is FDA-approved for HIV-associated lipodystrophy. It reduces visceral adipose tissue and improves metabolic profiles, though its use is currently limited to specific populations [70].

Monitoring of pituitary hormone agents includes clinical assessment, hormone levels (e.g., IGF-1, prolactin, cortisol), imaging for adenoma size, and evaluation for adverse effects. GH therapy, for instance, may cause edema, arthralgia, insulin resistance, or intracranial hypertension. Dopamine agonists can lead to nausea, orthostatic hypotension, and impulse control disorders in rare cases [71]. Future directions involve oral formulations of peptide hormones, targeted monoclonal antibodies against pituitary-derived growth factors, and gene therapy for congenital pituitary hormone deficiencies. Pharmacogenomics may also play a role in optimizing dosing and minimizing side effects in the future [72].

In conclusion, pituitary hormone agents are central to managing complex endocrine disorders. Tailored therapy based on pathophysiology, hormone assays, imaging, and individual response is essential for achieving therapeutic success.

6.7 New Frontiers: FGF21 Analogs and Hormonal Gene Therapies

The therapeutic landscape of endocrine and metabolic pharmacology is evolving rapidly, with novel agents such as fibroblast growth factor 21 (FGF21) analogues and hormonal gene therapies emerging as potential game changers. These innovative modalities aim to address limitations of current treatments by targeting root molecular defects, restoring hormonal homeostasis, and offering long-term benefits in metabolic disorders such as obesity, diabetes, and lipodystrophy [73].

FGF21 is an endocrine hormone predominantly secreted by the liver, with pleiotropic effects on glucose uptake, lipid metabolism, insulin sensitivity, and energy expenditure. It acts via fibroblast growth factor receptors (FGFR1c) in conjunction with the co-receptor β-klotho, primarily in adipose tissue and the central nervous system [74]. In preclinical models, FGF21 administration improves insulin sensitivity, reduces triglycerides, promotes weight loss, and enhances thermogenesis through brown adipose tissue activation [75].

Several FGF21 analogs and mimetics are in clinical development, including pegbelfermin, efruxifermin, and BIO89-100. These agents have shown promise in phase 2 trials for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus, and genetic lipodystrophies, demonstrating improvements in liver enzymes, glycemic indices, and lipid profiles [76]. Their long half-lives, resistance to proteolytic degradation, and sustained metabolic effects make them attractive candidates for chronic therapy.

Unlike conventional antidiabetic drugs, FGF21 analogs exert their effects independent of pancreatic β-cell function and do not carry a risk of hypoglycemia. This insulin-independent mechanism of action is particularly beneficial in advanced T2DM and insulin-resistant states [77]. Furthermore, FGF21 therapy is being explored for its neuroprotective, anti-inflammatory, and cardiovascular benefits, suggesting potential application beyond metabolic diseases [78].

Parallel to these developments, hormonal gene therapies are being pursued to offer curative options for congenital endocrine deficiencies and chronic hormonal disorders. Gene therapy strategies typically involve viral vectors commonly adeno-associated viruses (AAV) or lentiviruses engineered to deliver functional copies of defective genes into target tissues. This approach is

particularly relevant in disorders such as congenital adrenal hyperplasia (CAH), Laron syndrome (GH receptor deficiency), and hypoparathyroidism [79].

For example, preclinical studies using AAV vectors to deliver functional CYP21A2 in CAH models have demonstrated restoration of steroidogenesis and reversal of adrenal hyperplasia [80]. Similarly, experimental therapies targeting GH1 and GHRHR genes aim to restore physiological growth hormone secretion, eliminating the need for daily injections. Gene replacement for PTH gene mutations is being studied as a treatment for chronic hypoparathyroidism [81].

Challenges in hormonal gene therapy include vector immunogenicity, tissue-specific targeting, long-term gene expression, and regulation of hormone levels to avoid overcorrection. Nevertheless, early-phase clinical trials in monogenic endocrine disorders are demonstrating favourable safety and proof-of-concept efficacy [82].

In addition to replacement strategies, gene-editing technologies such as CRISPR-Cas9 are under investigation for permanent correction of genetic defects at the DNA level. These tools may ultimately enable one-time curative treatments for inherited metabolic and hormonal disorders. For example, CRISPR-based interventions for Wolfram syndrome (WFS1 mutations) are currently being explored for their therapeutic potential [83].

The integration of omics technologies (genomics, proteomics, metabolomics) is critical to identify patient subgroups who may benefit from these advanced therapies. Biomarkers derived from transcriptomic and epigenomic profiling can aid in selecting candidates for gene-based interventions and monitoring therapeutic efficacy [84].

Overall, the transition from symptom control to molecular repair and regeneration marks a paradigm shift in endocrine pharmacology. As these therapies progress through clinical development, they offer hope for durable remission or even cure in previously intractable endocrine conditions.

6.8 Drug Interactions and Monitoring in Endocrine Therapy

Drug interactions and therapeutic monitoring are critical aspects of endocrine pharmacology due to the narrow therapeutic index of many hormone-based therapies and the complexity of hormonal feedback mechanisms. Endocrine agents frequently interact with other medications at pharmacokinetic and pharmacodynamic levels, necessitating vigilant oversight to prevent adverse effects, therapeutic failure, or endocrine crisis [85].

Glucocorticoids, widely used for their anti-inflammatory and immunosuppressive effects, induce hepatic cytochrome P450 enzymes, particularly CYP3A4, leading to altered metabolism of co-administered drugs. For instance, glucocorticoids may reduce the efficacy of antidiabetic agents, potentiate hypokalemia when combined with loop or thiazide diuretics, and increase the risk of gastrointestinal bleeding when used with NSAIDs [86]. Conversely, drugs that inhibit CYP3A4 (e.g., ketoconazole, ritonavir) may increase systemic steroid exposure and risk of iatrogenic Cushing's syndrome [87].

Thyroid hormones, especially levothyroxine, are highly susceptible to interactions that impair absorption, including calcium supplements, iron, proton pump inhibitors, and bile acid sequestrants. These agents must be separated by several hours from LT4 administration. Enzyme inducers like carbamazepine and phenytoin accelerate LT4 metabolism, potentially necessitating dose escalation. Estrogens increase thyroxine-binding globulin (TBG), often requiring higher LT4 doses in women on hormone replacement therapy or oral contraceptives [88].

Antithyroid drugs such as methimazole and propylthiouracil carry risks of agranulocytosis, hepatotoxicity, and vasculitis, which require routine hematologic and hepatic monitoring. Concurrent

use with other bone marrow suppressants or hepatotoxic agents, such as azathioprine or methotrexate, elevates the risk of adverse outcomes and warrants caution [89].

Insulin and oral antidiabetic agents have substantial interaction profiles. Beta-blockers, while commonly prescribed in diabetic patients for cardiovascular protection, may mask hypoglycemia symptoms. ACE inhibitors and salicylates may potentiate insulin action and risk of hypoglycemia, whereas corticosteroids and atypical antipsychotics can increase insulin resistance [90]. SGLT2 inhibitors should be used cautiously in patients on loop diuretics due to the risk of volume depletion and hypotension [91].

GLP-1 receptor agonists and DPP-4 inhibitors are generally safe but may interact with medications affecting gastric motility or DPP-4 substrates such as certain chemokines and cytokines. Combined use of GLP-1 agonists with insulin or sulfonylureas increases the risk of hypoglycemia and mandates dose adjustments [92].

Pituitary hormone agents, including dopamine agonists like cabergoline, can interact with serotonergic agents (SSRIs, triptans) and dopamine antagonists (antipsychotics), leading to diminished efficacy or serotonin syndrome. Monitoring is essential in polypharmacy situations, especially in patients with psychiatric comorbidities [93].

Mineralocorticoid therapy, particularly fludrocortisone, poses risks of fluid retention, hypertension, and hypokalemia. Diuretics, especially potassium-wasting types, amplify these risks. Serum electrolytes and blood pressure should be closely monitored, especially in patients with renal impairment or on combination diuretic therapy [94].

Monitoring strategies in endocrine therapy vary by agent and indication. For levothyroxine, TSH is the primary marker, typically assessed every 6–8 weeks during titration and every 6–12 months thereafter. For insulin therapy, HbA1c, fasting plasma glucose, and self-monitoring blood glucose (SMBG) are standard. CGM provides dynamic insight into glycemic variability and time-in-range metrics [95].

Glucocorticoid therapy requires periodic monitoring of bone mineral density, fasting glucose, lipid profile, and ocular pressure. Bisphosphonate prophylaxis and calcium/vitamin D supplementation should be initiated in patients on chronic steroid therapy. For testosterone therapy, hematocrit, PSA, and liver enzymes must be monitored to prevent polycythemia, prostate enlargement, and hepatotoxicity [96].

Clinical pharmacogenomics is increasingly used to guide therapy. For example, polymorphisms in CYP2C9 and SLCO1B1 influence sulfonylurea and statin metabolism, respectively, while variants in TSHR or deiodinase genes may affect thyroid hormone responsiveness [97].

In conclusion, effective endocrine therapy requires proactive management of drug interactions and diligent monitoring protocols tailored to the pharmacologic agent and patient-specific factors. Multidisciplinary coordination among endocrinologists, pharmacists, and primary care providers enhances safety and therapeutic outcomes.

6.9 Individualized Endocrine Therapy

The emergence of individualized or precision endocrine therapy represents a major shift from traditional, population-based treatment paradigms toward a more personalized approach that accounts for patient-specific factors such as genetic profile, pharmacogenomics, metabolic state, comorbid conditions, and lifestyle. In endocrine pharmacology, where hormonal therapies affect multiple systems, such customization is essential to maximize therapeutic efficacy and minimize adverse outcomes [98].

Pharmacogenomics plays a pivotal role in tailoring endocrine therapies. Variations in genes encoding drug-metabolizing enzymes, hormone receptors, and transport proteins can significantly influence drug response. For example, polymorphisms in the CYP2C9 and CYP2C19 genes affect the metabolism of sulfonylureas, leading to either exaggerated hypoglycemic responses or therapeutic failure [99]. Similarly, SLCO1B1 variants affect statin uptake and may predispose individuals to myopathy when used for dyslipidemia in metabolic syndrome [100].

In thyroid pharmacology, mutations in DIO2 (encoding type 2 deiodinase) have been associated with suboptimal response to levothyroxine monotherapy. These patients may benefit from combination therapy with liothyronine (T3), although clinical guidelines remain cautious due to variability in outcomes and risk of cardiovascular events [101]. In adrenal replacement therapy, NR3C1 gene polymorphisms modulate glucocorticoid receptor sensitivity, potentially altering steroid requirements in Addison's disease or congenital adrenal hyperplasia [102].

Individualized therapy also considers age, sex, BMI, renal and hepatic function, and comorbidities. For example, in elderly patients with diabetes, therapeutic goals often emphasize avoidance of hypoglycemia and preservation of functional status, favoring agents with lower risk profiles such as DPP-4 inhibitors or basal insulin analogs [103]. In women with PCOS, combined oral contraceptives, insulin sensitizers, or anti-androgens are selected based on dominant symptoms (e.g., hirsutism vs. anovulation), metabolic risk, and fertility considerations [104].

Therapeutic drug monitoring (TDM) enables dose optimization for drugs with narrow therapeutic windows or variable pharmacokinetics, such as levothyroxine, insulin, and corticosteroids. Advanced techniques like mass spectrometry are increasingly being used for precise quantification of hormone levels and drug metabolites [105].

Clinical algorithms incorporating machine learning and artificial intelligence are being developed to personalize endocrine care. These tools analyze real-time data from continuous glucose monitors, wearable fitness trackers, and electronic health records to guide insulin dosing, dietary modifications, and medication adjustments [106]. AI-driven insulin dose calculators and CGM-integrated insulin pumps represent the forefront of individualized diabetes management.

Moreover, biomarkers such as adiponectin, hs-CRP, C-peptide, and IGF-1 are being explored for stratifying patients, predicting treatment response, and guiding therapy duration. For instance, patients with residual C-peptide may benefit from incretin-based therapies, while those with advanced β-cell loss may require early insulin initiation [107].

Behavioural and psychosocial factors also influence adherence and outcomes. Incorporating patient preferences, cultural beliefs, and psychological readiness into therapy planning ensures greater engagement and sustained lifestyle change. Motivational interviewing and shared decision-making models are now integrated into endocrine care, especially for chronic diseases like diabetes and obesity [108].

Digital health platforms enable remote monitoring, teleconsultation, and adherence tracking, expanding access to personalized care in rural or resource-limited settings. Mobile apps with customized alerts, feedback systems, and educational content have demonstrated improved medication adherence and metabolic control [109].

In the future, gene-editing technologies, bio printed endocrine tissues, and implantable hormone delivery devices may allow unprecedented personalization of endocrine therapy. These advances, while still experimental, point toward a future in which endocrine disorders can be managed with curative precision [110].

In summary, individualized endocrine therapy is no longer a theoretical ideal but an emerging clinical reality, driven by advancements in genomics, data science, and patient-centered care. Tailoring treatment to the unique biological and social context of each patient holds the key to optimal endocrine pharmacotherapy.

6.10 CONCLUSION

Endocrine and metabolic pharmacology has witnessed transformative progress over the past decade, moving from generalized treatment approaches toward highly individualized, mechanism-based therapies. The management of conditions like diabetes, obesity, thyroid and adrenal disorders, and pituitary dysfunctions now relies on an expanding arsenal of drugs including insulin analogs, SGLT2 inhibitors, GLP-1 receptor agonists, and hormone biosimilars that target specific physiological pathways with greater precision and safety.

Technological innovations such as continuous glucose monitoring, smart insulin delivery systems, and AI-driven platforms are improving therapeutic outcomes and patient engagement. Furthermore, the integration of pharmacogenomics and biomarker-driven strategies enables clinicians to tailor treatments based on genetic and metabolic profiles, optimizing efficacy while minimizing adverse effects.

Emerging therapies such as FGF21 analogs, dual/triple incretin receptor agonists, and hormonal gene therapies represent the next frontier, promising not only better disease control but potential cures for select monogenic and metabolic disorders. However, these advancements also underscore the need for comprehensive monitoring, interdisciplinary collaboration, and patient education to ensure effective and sustainable care.

In summary, endocrine pharmacology is rapidly evolving into a precision-oriented discipline. By aligning drug development with personalized medicine, digital tools, and molecular insights, it holds the potential to significantly enhance quality of life and clinical outcomes for patients worldwide.

REFERENCES

1. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364–73.
2. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–5.
3. Rosen CJ, Adler RA, Burguera B, et al. Hormones and metabolism: an integrative overview. Endocr Rev. 2021;42(1):1–23.
4. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes. Circulation. 2019;139(22):2536–51.
5. Heinemann L. Biosimilar insulins: how will this story evolve? Diabetes Technol Ther. 2015;17(8):545–54.
6. Cavalli M, Pan G, Nord H, Wallerman O, Wadelius C. Genetic variation in the CYP450 gene family and its implications for personalized therapy. Curr Drug Metab. 2016;17(6):513–27.
7. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603.

8. Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T. AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism. Cell Rep Med. 2020;1(3):100057.
9. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes 2021. Diabetes Care. 2021;44(Suppl 1):S15–33.
10. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174–83.
11. Riddle MC, Rosenstock J, Gerich J. Insulin glargine–based therapy: basal insulin therapy in type 2 diabetes. Diabetes Care. 2003;26(11):3080–6.
12. Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espeland MA, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized trial. Diabetes Obes Metab. 2015;17(9):804–12.
13. Pickup JC. Insulin pumps. Int J Clin Pract Suppl. 2011;(170):16–9.
14. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384–95.
15. Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018;361:k1310.
16. Brown L, Edelman SV, Santiago JV. The next generation of insulin: glucose-responsive insulin. Diabetes Technol Ther. 2019;21(6):345–52.
17. Liu M, Hodish I, Haataja L, et al. Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth. Trends Endocrinol Metab. 2010;21(11):652–9.
18. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report. Diabetes Care. 2018;41(12):2669–701.
19. Heinemann L, Kapitza C, Nosek L, et al. Insulin biosimilars: what are the regulatory challenges? Diabetes Technol Ther. 2014;16(12):835–43.
20. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypoglycemia in adults with type 1 diabetes. Diabetes Technol Ther. 2018;20(10):673–82.
21. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–36.
22. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium–glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–31.
23. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
24. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of DPP-4 inhibitors. Endocr Rev. 2014;35(6):992–1019.
25. Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.
26. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
27. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6(4):275–86.
28. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414–25.
29. Nauck M, Stöckmann F, Ems W, et al. Combination therapies in type 2 diabetes. Diabetes Obes Metab. 2014;16(Suppl 1):30–40.

30. Blonde L, Rosenstock J, Triplitt C. Insulin and incretin-based combination therapy. Endocr Pract. 2014;20(6):613–24.
31. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide in type 2 diabetes. N Engl J Med. 2021;385(6):503–15.
32. Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation. 2012;125(13):1695–703.
33. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nat Rev Neurosci. 2014;15(6):367–78.
34. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
35. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
36. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity. 2009;17(9):1730–5.
37. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS). Diabetes Care. 2004;27(1):155–61.
38. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
39. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403–13.
40. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity. Endocr Pract. 2015;21(3):341–55.
41. Clement K, van Gaal L. New therapeutic approaches to the treatment of obesity. Best Pract Res Clin Endocrinol Metab. 2021;35(2):101539.
42. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–751.
43. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults. Endocr Pract. 2012;18(6):988–1028.
44. Colucci P, Yue CS, Ducharme MP, et al. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2013;9(1):40–7.
45. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of oral liquid levothyroxine. J Endocrinol Invest. 2014;37(9):805–12.
46. Ross DS, Burch HB, Cooper DS, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism. Thyroid. 2016;26(10):1343–421.
47. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis. J Clin Endocrinol Metab. 2011;96(12):3562–75.
48. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–17.
49. Bartalena L, Tanda ML, Piantanida E, Lai A. Management of Graves' orbitopathy. Nat Rev Endocrinol. 2021;17(4):207–22.
50. Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev. 1998;50(1):89–105.
51. Pilo A, Iervasi G, Vitek F. Thyromimetics: a strategy for metabolic disorders. Curr Opin Investig Drugs. 2010;11(5):482–90.
52. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency. J Clin Endocrinol Metab. 2016;101(2):364–89.

53. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998;94(6):557–72.
54. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.
55. Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use. J Clin Endocrinol Metab. 2015;100(6):2171–80.
56. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152–67.
57. Hahner S, Ross RJ, Arlt W. Adrenal crisis. N Engl J Med. 2015;373(10):954–62.
58. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 2009;28(7):749–56.
59. Van Staa TP, Leufkens HG, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.
60. Schäcke H, Rehwinkel H, Asadullah K. SEGRMs: selective glucocorticoid receptor modulators. Curr Opin Investig Drugs. 2007;8(5):403–10.
61. Nieman LK, Biller BMK, Findling JW, et al. Diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–40.
62. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881–93.
63. Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937–50.
64. Allen DB. Growth hormone therapy for short stature: efficacy and safety. Curr Opin Pediatr. 2011;23(4):415–21.
65. Colao A, Auriemma RS, Pivonello R, et al. Treatment of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2009;94(5):1500–8.
66. Molitch ME. Management of prolactinomas during pregnancy. Endocrinol Metab Clin North Am. 2015;44(1):181–8.
67. Bornstein SR, Predel HG, Laue C, et al. Cosyntropin stimulation testing. Endocr Rev. 2008;29(5):761–71.
68. Fleseriu M, Pivonello R, Young J, et al. Efficacy and safety of osilodrostat in Cushing's disease. Lancet Diabetes Endocrinol. 2019;7(11):834–46.
69. Verbalis JG. Disorders of water balance. Endocrinol Metab Clin North Am. 2002;31(2):337–52.
70. Falutz J, Allas S, Blot K, et al. Metabolic effects of tesamorelin in HIV-associated lipodystrophy. N Engl J Med. 2010;362(5):407–17.
71. Molitch ME. Diagnosis and treatment of pituitary adenomas. J Clin Endocrinol Metab. 2017;102(2):411–22.
72. Liu R, Bringas JR, Habib NA. Gene therapy in endocrine disorders. Front Horm Res. 2016;46:146–64.
73. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and insulin resistance. J Clin Endocrinol Metab. 2010;95(3):1055–61.
74. Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol. 2016;78:223–41.
75. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333–40.
76. Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin in nonalcoholic steatohepatitis: a randomized phase 2a study. Lancet. 2019;392(10164):2705–17.
77. Talukdar S, Zhou Y, Li D, et al. A long-acting FGF21 analog improves metabolic parameters in obese rhesus monkeys. Cell Metab. 2016;23(3):427–40.

78. Marcelin G, Jo YH, Li X, Schwartz GJ, Chua S Jr. Central action of FGF21 modulates energy expenditure and insulin sensitivity. J Clin Invest. 2014;124(9):4195–208.
79. Chittiboina P, Lonser RR. Pituitary gene therapy: a new horizon in neuroendocrinology. Nat Rev Endocrinol. 2019;15(11):709–20.
80. Merke DP, Keil MF, Jones JV, et al. CYP21A2 gene therapy in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2018;103(10):3830–40.
81. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone in hypoparathyroidism. N Engl J Med. 2013;369(7):629–39.
82. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–78.
83. Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636–46.
84. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
85. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 2004;57(1):6–14.
86. El-Hadi H, Bashir M, Al Momen S. Drug interactions of glucocorticoids. Am J Med Sci. 2018;355(1):25–30.
87. Molloy ES. Drug interactions in autoimmune diseases. Best Pract Res Clin Rheumatol. 2009;23(2):201–13.
88. Virili C, Antonelli A, Santaguida MG, Centanni M. Gastrointestinal interference with levothyroxine absorption. Endocrine. 2019;66(2):314–20.
89. Cooper DS. Adverse effects of antithyroid drugs. Endocrinol Metab Clin North Am. 1998;27(1):225–47.
90. Holstein A, Beil W. Oral antidiabetic drug interactions: clinical relevance. Drug Saf. 2009;32(6):449–71.
91. Inzucchi SE, Zinman B, Wanner C, et al. SGLT2 inhibitors and cardiovascular risk. Circulation. 2016;134(10):752–72.
92. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormones. Cell Metab. 2013;17(6):819–37.
93. Karavitaki N, Wass JAH. Pituitary disease and psychiatric symptoms. Clin Endocrinol (Oxf). 2017;87(6):532–41.
94. Thomason J, Thompson CJ. Monitoring of mineralocorticoid therapy. J Clin Endocrinol Metab. 2015;100(3):705–12.
95. Battelino T, Danne T, Bergenstal RM, et al. Continuous glucose monitoring: a key component of modern diabetes management. Diabetologia. 2019;62(7):1219–28.
96. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715–44.
97. Cavalli M, Pan G, Nord H, Wallerman O, Wadelius C. Genetic variation and drug response. Curr Drug Metab. 2016;17(6):513–27.
98. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301–4.
99. Becker ML, Visser LE, van Schaik RH, et al. CYP2C9 polymorphisms and response to sulfonylureas. Pharmacogenomics J. 2008;8(2):129–36.
100. Ramsey LB, Johnson SG, Caudle KE, et al. Pharmacogenomics of statins. Clin Pharmacol Ther. 2014;96(4):423–8.
101. Panicker V, Cluett C, Shields B, et al. A common variation in the DIO2 gene and response to L-T4 therapy. J Clin Endocrinol Metab. 2009;94(5):1623–9.

102. Panarelli M, Krane E, Dotson S, et al. NR3C1 polymorphisms and glucocorticoid sensitivity. Endocr Res. 2016;41(4):253–60.
103. Sinclair A, Saeedi P, Kaundal A, et al. Diabetes in older adults: standards of medical care. Diabetes Care. 2023;46(Suppl 1):S195–209.
104. Teede HJ, Misso ML, Costello MF, et al. Recommendations for PCOS management. Fertil Steril. 2018;110(3):364–79.
105. Soldin OP, Soldin SJ. Thyroid hormone testing by tandem mass spectrometry. Clin Biochem. 2011;44(1):89–94.
106. Bergenstal RM, Klonoff DC, Garg SK, et al. AI-assisted insulin titration. Diabetes Technol Ther. 2021;23(4):248–54.
107. Nauck MA, Meier JJ. Biomarkers for individualized diabetes care. Diabetologia. 2018;61(4):685–9.
108. Elwyn G, Frosch D, Thomson R, et al. Shared decision making in health care. BMJ. 2012;344:e256.
109. Greenwood DA, Gee PM, Fatkin KJ, et al. Digital health coaching for diabetes. J Diabetes Sci Technol. 2017;11(1):182–9.
110. Araki R, Ueno S, Shibata S, et al. Gene therapy and future endocrine treatments. Endocr J. 2022;69(7):735–42.

1

Dr. SriKalyani Vemuri
Associate Professor, Department of Pharmaceutical Analysis
Sri Venkateswara College of Pharmacy, Madhapur, Hyderabad.

2

Mr. Varaha Narasimharao. C
Associate professor, Shantiniketan college of Pharmacy,
Dhotre, Ahilyanahar, Maharashtra, India